GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bolt Biotherapeutics Inc (NAS:BOLT) » Definitions » Pretax Margin %

Bolt Biotherapeutics (Bolt Biotherapeutics) Pretax Margin % : -204.99% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Bolt Biotherapeutics Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Bolt Biotherapeutics's Pre-Tax Income for the three months ended in Mar. 2024 was $-10.81 Mil. Bolt Biotherapeutics's Revenue for the three months ended in Mar. 2024 was $5.27 Mil. Therefore, Bolt Biotherapeutics's pretax margin for the quarter that ended in Mar. 2024 was -204.99%.

The historical rank and industry rank for Bolt Biotherapeutics's Pretax Margin % or its related term are showing as below:

BOLT' s Pretax Margin % Range Over the Past 10 Years
Min: -26289.18   Med: -7824.68   Max: -556.59
Current: -556.59


BOLT's Pretax Margin % is ranked worse than
65.86% of 1028 companies
in the Biotechnology industry
Industry Median: -155.495 vs BOLT: -556.59

Bolt Biotherapeutics Pretax Margin % Historical Data

The historical data trend for Bolt Biotherapeutics's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bolt Biotherapeutics Pretax Margin % Chart

Bolt Biotherapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Pretax Margin %
Get a 7-Day Free Trial -14,180.00 -26,289.18 -7,824.68 -1,537.76 -878.58

Bolt Biotherapeutics Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -929.90 -1,260.08 -643.08 -857.01 -204.99

Competitive Comparison of Bolt Biotherapeutics's Pretax Margin %

For the Biotechnology subindustry, Bolt Biotherapeutics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bolt Biotherapeutics's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bolt Biotherapeutics's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Bolt Biotherapeutics's Pretax Margin % falls into.



Bolt Biotherapeutics Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Bolt Biotherapeutics's Pretax Margin for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-69.197/7.876
=-878.58 %

Bolt Biotherapeutics's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as

Pretax Margin=Pre-Tax Income (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=-10.811/5.274
=-204.99 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bolt Biotherapeutics  (NAS:BOLT) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Bolt Biotherapeutics Pretax Margin % Related Terms

Thank you for viewing the detailed overview of Bolt Biotherapeutics's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Bolt Biotherapeutics (Bolt Biotherapeutics) Business Description

Traded in Other Exchanges
Address
900 Chesapeake Drive, Redwood, CA, USA, 94063
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems.
Executives
William P. Quinn officer: Chief Financial Officer SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BOULEVARD, SUITE 400, SOUTH SAN FRANCISCO CA 94080
Edgar Engleman director 575 HIGH STREET, STE 201, PALO ALTO CA 94301
Vivo Capital Fund Viii, L.p. 10 percent owner 505 HAMILTON AVENUE, SUITE 200, PALO ALTO CA 94301
Laura Berner director C/O BOLT BIOTHERAPEUTICS, INC., 900 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Novo Holdings A/s 10 percent owner TUBORG HAVNEVEJ 19, HELLERUP G7 2900
James Healy director 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Brian O'callaghan director 550 HILLS DRIVE, 3RD FLOOR, BEDMINSTER NJ 07921
Frank D. Lee director C/O FORMA THERAPEUTICS HOLDINGS, INC., 500 ARSENAL STREET, SUITE 100, WATERTOWN MA 02472
Kathleen Laporte director
Miller Richard A Md director PHARMACYCLICS INC, 995 E ARQUES AVE, SUNNYVALE CA 94085-4521
Mahendra Shah director 2250 HOLCOMBE BLVD, HOUSTON TX 77030
Grant Yonehiro officer: Chief Business Officer C/O MAXYGEN, INC., 515 GALVESTON DRIVE, REDWOOD CITY CA 94063
Randall C Schatzman director, officer: Chief Executive Officer 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011
David Dornan officer: Chief Scientific Officer C/O BOLT BIOTHERAPEUTICS, INC., 640 GALVESTON DRIVE, REDWOOD CITY CA 94063
Edith A. Perez officer: Chief Medical Officer C/O BOLT BIOTHERAPEUTICS, INC., 640 GALVESTONE DRIVE, REDWOOD CITY CA 94063

Bolt Biotherapeutics (Bolt Biotherapeutics) Headlines

From GuruFocus

Bolt Biotherapeutics to Present at February Investor Conferences

By Stock market mentor Stock market mentor 02-01-2023